drugset / Trial / NCT00714649
Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery
Phase 1/2
Completed
34 enrolled
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Merck Serono International SA · collabMerck Sharp & Dohme LLC · collab
Parallel-groupOpen-labelTreatment
Summary
Primary diagnose HNSCC carcinoma patients eligible for curative surgery will be proposed the addition of 2 or 3 neoadjuvant cetuximab infusions. The main objective is to reduce to a minimal delay the time elapsing between last infusion and surgery. Iterative biomarkers will be taken at 6 time points permitting to investigate expression gen profile and protein mutation.
Timeline
- Start
- 2008-07
- Primary completion
- 2011-05
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |